Literature DB >> 12745736

Postoperative radiotherapy after prostatectomy--a review.

Bo Lennernäs1, Maliha Edgren, Michael Häggman, Bo J Norlén, Sten Nilsson.   

Abstract

PURPOSE: The management of prostate adenocarcinomas using postoperative irradiation is a controversial question. The purpose of this study was to review the literature on the subject.
MATERIAL AND METHODS: A total of 417 articles dealing with postoperative radiotherapy after radical prostatectomy in English literature (1990-2002) were reviewed in aspects of effect on survival, time of irradiation, risk factors, dose and technique and side effects. RESULTS AND DISCUSSION: No randomised studies have been performed and therefore no definitive conclusive data can be made concerning the efficiency of the concept. However, postoperative radiotherapy appears to increase local control preferably in pT3/4 prostatic carcinomas with seminal vesicles involvement and/or positive margins and/or high Gleason score and high postoperative PSA level. It has not been shown to improve survival. Severe side effects are reported in a low frequency. However, postoperative irradiation can cause severe side effects and postoperative adjuvant/salvage treatments should be delivered earliest 3-6 months after surgery and the total dose delivered to the prostate bed should be 65-70 Gy. Postoperative radiotherapy induces improved local control in patients with positive surgical margins and in patients with a local relapse, preferably if the tumour is small (i.e. PSA <1-2 ng/mL).

Entities:  

Mesh:

Year:  2003        PMID: 12745736     DOI: 10.1080/00365590310008613

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1. 

Authors:  Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

2.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Authors:  Noriko N Yokoyama; Shujuan Shao; Bang H Hoang; Dan Mercola; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2014-04-15

3.  Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.

Authors:  Zhuangzhuang Zhang; Lijun Cheng; Jie Li; Elia Farah; Nadia M Atallah; Pete E Pascuzzi; Sanjay Gupta; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-04-26       Impact factor: 12.701

4.  Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.

Authors:  Dingwei Ye; Wei Zhang; Lulin Ma; Chuanjun Du; Liping Xie; Yiran Huang; Qiang Wei; Zhangqun Ye; Yanqun Na
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

Review 5.  Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.

Authors:  Changhao Chen; Tianxin Lin; Yu Zhou; Doudou Li; Kewei Xu; Zhihua Li; Xinxiang Fan; Guangzheng Zhong; Wang He; Xu Chen; Xianyin He; Jian Huang
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.